Trial in Parkinson's disease shows that for long-term treatment levodopa is better than newer drugs

An NIHR Health Technology Assessment (HTA) Programme-funded study has published its findings in The Lancet. For long-term treatment of newly diagnosed Parkinson’s disease (PD), the old drug levodopa provides better mobility and a higher quality of life than the two main alternatives, dopamine agonists (DA) and monoamine oxidase type B inhibitors (MAOBI), according to...
Source: NIHR Evaluation, Trials and Studies News - Category: American Health Source Type: news